Poncirin

Poncirin: A Comprehensive Reference

1. Identity and Chemical Characterization

Chemical Name and Structure

Poncirin is a flavanone glycoside that is 4′-methoxy-5,7-dihydroxyflavanone attached to a neohesperidose (alpha-L-rhamnopyranosyl-(1→2)-beta-D-glucopyranose) residue via a glycosidic linkage. It is therefore classified structurally as the 7-O-neohesperidoside of the flavanone aglycone isosakuranetin. Poncirin is a member of the 4′-methoxyflavanones, a neohesperidoside, a monomethoxyflavanone, a disaccharide derivative, and a flavanone glycoside.

Its molecular formula is C₂₈H₃₄O₁₄, with an exact mass of 594.19 and a molecular weight of 594.57. The IUPAC name is (S)-7-(((2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-(((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)-5-hydroxy-2-(4-methoxyphenyl)chroman-4-one. The CAS registry number for poncirin is 14941-08-3. The compound belongs to the broader class of flavanones that are recognized as principal flavanone glycosides found in nature: hesperidin, neohesperidin, naringin, narirutin, eriocitrin, neoeriocitrin, poncirin, neoponcirin, didymin, prunin, and sakuranin are among the main flavanone glycosides.

Botanical Source and Natural Occurrence

Poncirus trifoliata (L.) Raf., a deciduous or semi-deciduous shrub native to China and Korea, also known as "trifoliate orange," is closely related to the genus Citrus. The species is unusual among citrus for having deciduous, compound leaves and pubescent (downy) fruit. It is native to northern China and Korea, and is also known as the Japanese bitter-orange (karatachi), hardy orange, or Chinese bitter orange.

Poncirin has been isolated from the fruits of Poncirus trifoliata. Poncirin has also been reported in Micromeria graeca, Citrus medica, and other organisms. Poncirin was isolated from four different tissues (flavedo, albedo, segment membrane, and juice sac) of Ougan fruit (Citrus reticulate cv. Suavissima). Citrus fruits contain abundant flavonoids such as hesperidin, naringin, nobiletin, and poncirin, which exhibit anticancer effects in different cancer cells.

Among the bioactive components of P. trifoliata, poncirin accounts for approximately 6% of the total composition, making it the most abundant component, along with other compounds such as naringin, hesperidin, and sinensetin.

Common Forms and Preparations

Ponciri Fructus is a crude drug obtained from the dried immature fruits of Poncirus trifoliata (L.) Raf. (Syn. Citrus trifoliata L.). Its bitter fruits are commonly used in dried and powdered marmalades. In research and commercial contexts, poncirin is available as an isolated, high-purity reference compound extracted from plant material. In analytical and experimental studies, flavonoids from P. trifoliata fruit ethanol extract are identified using UPLC-Q-TOF-MS; the 40% ethanol extract has been shown to yield the highest concentrations of total phenolic content, total flavonoid content, and flavonoids.

2. Traditional and Historical Use

East Asian Medical Traditions

Although the ethnomedicinal use of P. trifoliata has a very long history in Korea, Japan, and China, scientific investigations focused on in-depth phytochemistry are limited. Concerning ethnomedicinal uses, Ponciri Fructus is extensively used in traditional Korean, Chinese, and Kampo medicines to mitigate allergic reactions, inflammation, edema, digestive complications, respiratory problems, spleen-related problems, liver complications, neuronal pain, hyperlipidemia, rheumatoid arthritis, cardiovascular problems, hernia, sinusitis, and insomnia.

In Korea, P. trifoliata has long been used as an anti-inflammatory and antiallergic agent to treat gastrointestinal disorders and pulmonary diseases such as indigestion, constipation, chest fullness, chest pain, bronchitis, and sputum. In the theory of traditional medicine, the immature fruit of P. trifoliata can break stagnation of qi and remove food retention, resolve phlegm, and eliminate mass. Accordingly, it is used to treat indigestion, constipation due to accumulation of heat, and dysentery.

The mature fruit possesses anticancer and anti-inflammatory activities. Extracts of the dried, immature fruit, Poncirus fructus (PF), are widely used as a traditional medicine for ameliorating symptoms of digestive dysfunction in East Asia.

Ponciri Fructus is extensively used in traditional Korean, Chinese, and Kampo medicines to mitigate allergic reactions, inflammation, edema, digestive complications, respiratory problems, spleen-related problems, liver complications, neuronal pain, hyperlipidemia, rheumatoid arthritis, cardiovascular problems, hernia, sinusitis, and insomnia. A Korean traditional formulation, Ojeok-san (a combination of 17 different crude drugs including Ponciri Fructus), has been used as a folk remedy for the mitigation of numerous pathological conditions such as neuronal pain, hyperlipidemia, fever, and rheumatoid arthritis. Ethnomedicinally, Ponciri Fructus is extensively being used as a prokinetic agent, to improve the abnormal contraction of the uterus, to ameliorate the flow of blood, and to cure gastroesophageal reflux disease.

The fruits of the trifoliate orange are widely used in medical traditions of East Asia as a treatment for allergic inflammation. The drug is official or recognized in traditional pharmacopeias of Korea, China, and Japan (Kampo), where it is listed under the names Ponciri Fructus or Zhǐshí/Zhǐké (depending on maturity stage) in Chinese traditional formulations.

3. Key Constituents and Active Compounds of Poncirus trifoliata

Poncirin itself is the principal flavanone glycoside found in Poncirus trifoliata, but the plant contains numerous other bioactive constituents. Even though various parts of the plant such as root, stem bark, leaves, flower, fruits, and seeds are being examined for their bioactive compounds, the majority of investigations have been focused on the immature fruits. Several studies have shown that the dried immature fruits are a major source of diverse classes of bioactive compounds, namely flavonoids, terpenoids, coumarins, phytosterols, and alkaloids.

UPLC analysis of P. trifoliata extracts has identified four flavanones (poncirin, naringin, isosakuranetin, and naringenin), one chalcone (2′,6′-dihydroxy-4-methoxychalcone-4′-O-neohesperidoside), and two triterpenes. Additional isolates from P. trifoliata include limonin, imperatorin, beta-sitosterol, and various coumarins and alkaloids found in different plant parts.

The Principal Metabolite: Ponciretin

An important feature of poncirin's biological activity relates to its intestinal metabolism. Administration of poncirin, a major flavonoid of Ponciri Fructus, after metabolism gets converted into ponciretin and inhibits the growth of Helicobacter pylori in the intestine with a minimum inhibitory concentration (MIC) of 10–20 μg/mL. Ponciretin is the aglycone form of poncirin (5,7-dihydroxy-4′-methoxyflavanone, also known as isosakuranetin) generated when intestinal bacteria cleave the neohesperidose sugar moiety.

4. Established Mechanisms of Action

Anti-Inflammatory Mechanisms

Poncirin exhibits inhibitory activity against lipopolysaccharide (LPS)-induced prostaglandin E2 and interleukin-6 (IL-6) production. In greater mechanistic detail, poncirin inhibits LPS-induced iNOS, COX-2, and cytokine expression through NF-κB inactivation in RAW 264.7 macrophage cells. In cell-based assays, poncirin inhibits LPS-induced NF-κB DNA-binding activity, as well as production of nitric oxide and prostaglandin E2 (PGE2) in RAW 264.7 cells.

In naringinase-treated P. trifoliata extract preparations, reduced ROS production, lower inflammatory mediators (NO and PGE2), extracellular cytokines (TNF-α and IL-1β), and downregulation of COX-2 and intracellular cytokines (IL-1β and IL-6) gene expression have been observed in RAW 264.7 cells.

Apoptosis Induction (Extrinsic Pathway)

Poncirin could inhibit the proliferation of AGS gastric cancer cells in a dose-dependent manner. Poncirin induced accumulation of sub-G1 DNA content, apoptotic cell population, apoptotic bodies, chromatin condensation, and DNA fragmentation in a dose-dependent manner in AGS cells. The expression of Fas Ligand (FasL) protein was up-regulated dose-dependently in poncirin-treated AGS cells; poncirin in AGS cells induced activation of Caspase-8 and -3, and subsequent cleavage of poly(ADP-ribose) polymerase (PARP). Inhibitor studies confirmed that the induction of caspase-dependent apoptotic cell death in poncirin-treated AGS cells was led by the Fas death receptor. Poncirin did not show any effect on mitochondrial membrane potential (ΔΨm), pro-apoptotic proteins (Bax and Bak), or anti-apoptotic protein (Bcl-xL) in AGS-treated cells, with no activation of the mitochondrial apoptotic protein caspase-9. This indicates that the mitochondrial-mediated pathway is not involved in poncirin-induced cell death in gastric cancer.

Bone Metabolism: Anti-Osteoclastic Pathways

The receptor activator of NF-κB ligand (RANKL) is a member of the TNF superfamily and is a key mediator of osteoclast differentiation. A flavanone glycoside isolated from the fruit of Poncirus trifoliata, poncirin has anti-allergic, hypocholesterolemic, anti-inflammatory, and anti-platelet activities. Reduced formation of RANKL-stimulated TRAP-positive multinucleated cells (a morphological feature of osteoclasts) has been observed after poncirin exposure. Real-time qPCR analysis showed suppression of the RANKL-mediated induction of key osteoclastogenic molecules such as NFATc1, TRAP, c-Fos, MMP9, and cathepsin K after poncirin treatment. Poncirin also inhibited the RANKL-mediated activation of NF-κB and, notably, JNK, without changes in ERK and p38 expression in RAW264.7 cells.

Intestinal Immune Modulation (TLR4 / Th17–Treg Axis)

Poncirin regulates the balance of Th17/Treg cells by inhibiting the differentiation of Th17 cells and promoting the differentiation of Treg cells in an animal model of trinitrobenzene sulfonic acid (TNBS)-induced colitis.

Neuroprotective Mechanisms

Poncirin exhibits neuroprotective effects by inhibiting the NOX4/ROS/NLRP3 axis activation in the oxygen-glucose deprivation/reoxygenation (OGD/R) neuronal injury model.

5. Scientific Evidence by Area of Activity

Important caveat: Virtually all research on poncirin to date has been conducted in cell culture (in vitro) and animal models (in vivo in rodents). As of the time of writing, there is no published evidence from randomized controlled trials or other controlled clinical studies in humans specifically examining poncirin as an isolated compound. Evidence throughout this section is therefore preclinical unless otherwise noted, and its clinical relevance remains unestablished.

5.1 Anti-Inflammatory Activity

Pharmacological studies and clinical practices demonstrated that poncirin and its metabolites have multiple activities, such as anti-inflammatory properties, protective effects on potential gastric disease, defense against bacterial or viral infections and stresses, and promotion of osteoblast differentiation in mesenchymal stem cells.

The best-characterized in vitro evidence for anti-inflammatory action comes from macrophage studies in which LPS-stimulated RAW 264.7 cells were treated with poncirin across concentrations of 25–100 µM. Poncirin (25–100 µM) inhibits LPS-induced NF-κB DNA-binding activity, as well as production of nitric oxide (NO) and prostaglandin E2 (PGE2) in RAW 264.7 cells. These are mechanistic cell-culture findings; no human trials have replicated or extended them.

5.2 Gastric Protection and Gastrointestinal Disorders

P. trifoliata has been widely used in traditional medicine to treat gastro-intestinal disorders, including digestive ulcers, gastritis, dysentery, and inflammation.

The key preclinical gastroprotection study (Lee et al., 2009) examined poncirin isolated from Poncirus trifoliata fruit in rat models. The effects of Poncirus trifoliata (Ponciri Fructus, PF) extract and its constituents such as neohesperidin and poncirin on gastritis in rats and human gastric cancer cells were investigated. The PF 70% ethanol extracts showed approximately 11.38% of acid-neutralizing capacities and cytotoxicity (IC50=85.39 µg/mL) against human AGS gastric cancer cells. Poncirin (100 mg/kg) significantly inhibited 60.0% of HCl/ethanol-induced gastric lesions and increased the mucus content. From these results, it was suggested that neohesperidin and poncirin isolated from PF may be useful for the treatment and/or protection of gastritis. These findings are from rat models administered high oral doses; their translatability to humans is uncertain.

Extract of Ponciri Fructus hastens gastric emptying and improves mucus secretion. The activity of the fruit is attributed to the presence of bioactive compounds such as poncirin (by reducing gastric lesion induced by HCl), naringin (by preventing gastric ulcers), hesperidin (by improving delayed gastric emptying), and neohesperidin (by stimulating mucus secretion).

Regarding gastroesophageal reflux disease and irritable bowel syndrome, PF, a traditional medicinal botanical drug, has long been utilized in East Asian medicine for the treatment of various GI disorders. It has been reported to possess anti-inflammatory, prokinetic, and analgesic properties. Previous studies have shown that PF extracts can enhance GI motility, regulate smooth muscle contraction, and exert protective effects against colitis and gastric ulcers. The bioactive metabolites in PF, such as naringin and poncirin, have been implicated in modulating gut motility and reducing inflammation, further supporting its potential therapeutic role in IBS and related disorders. These observations derive from preclinical and traditional-use data, not clinical trials.

5.3 Anti-Helicobacter pylori Activity

Poncirin was isolated from a water extract of the fruits of Poncirus trifoliata and metabolized by human intestinal bacteria. Among the metabolites generated, ponciretin (5,7-dihydroxy-4′-methoxyflavanone), the main metabolite, most potently inhibited the growth of H. pylori, with a minimum inhibitory concentration (MIC) of 10–20 µg/mL. However, poncirin itself and its other metabolites, except ponciretin, did not inhibit the growth of H. pylori, nor did they inhibit H. pylori urease. This is a notable finding: the antibacterial activity against H. pylori is attributed not to poncirin directly but to its metabolite ponciretin generated by gut bacterial metabolism. This work was conducted in vitro; no clinical trials have evaluated this activity.

5.4 Anticancer Activity

Poncirin, a natural bitter flavanone glycoside abundantly present in many species of citrus fruits, has various biological benefits such as anti-oxidant, anti-microbial, anti-inflammatory, and anti-cancer activities. However, all available anticancer evidence is preclinical (cell line or animal model studies).

Gastric cancer: The anti-cancer effects of poncirin were investigated in AGS human gastric cancer cells (gastric adenocarcinoma). Poncirin could inhibit the proliferation of AGS cells in a dose-dependent manner. Poncirin induced accumulation of sub-G1 DNA content, apoptotic cell population, apoptotic bodies, chromatin condensation, and DNA fragmentation in a dose-dependent manner in AGS cells. Additionally, in a separate in vitro model, poncirin inhibits the growth of SGC-7901 gastric cancer cells when used at concentrations ranging from 5 to 25 µg/mL. These are cell-culture observations only.

Mechanism of apoptosis (extrinsic pathway): Inhibitor studies' results confirm that the induction of caspase-dependent apoptotic cell death in poncirin-treated AGS cells was led by the Fas death receptor. Poncirin did not show any effect on mitochondrial membrane potential (ΔΨm), pro-apoptotic proteins (Bax and Bak), and anti-apoptotic protein (Bcl-xL) in AGS-treated cells, with no activation of the mitochondrial apoptotic protein caspase-9. This result suggests that the mitochondrial-mediated pathway is not involved in poncirin-induced cell death in gastric cancer.

Other cancer types: Pharmacological data analysis has also revealed the biological application of poncirin against bone loss, inflammation, colitis, human gastric cancer, gastritis, liver injury, and Alzheimer's disease. Separate cell-based work has extended anticancer observations to breast cancer cell lines. Poncirin exists in many citrus fruits, and it has been found that it can promote AGS cell apoptosis and play an anti-cancer role. No human clinical data exist for any anticancer indication.

5.5 Bone Health: Osteoporosis and Osteoclastogenesis

The effect of poncirin on bone biology has been examined in two types of preclinical models: cell-culture osteoclast-differentiation assays and an in vivo glucocorticoid-induced osteoporosis (GIO) mouse model.

In the osteoclast differentiation study (published in Biomolecules and Therapeutics, 2020), the effect of poncirin on osteoclast differentiation of RANKL-stimulated RAW264.7 cells was investigated. Reduced formation of RANKL-stimulated TRAP-positive multinucleated cells was observed after poncirin exposure. Real-time qPCR analysis showed suppression of the RANKL-mediated induction of key osteoclastogenic molecules such as NFATc1, TRAP, c-Fos, MMP9, and cathepsin K after poncirin treatment. Furthermore, the in vivo efficacy of poncirin was assessed in the LPS-induced bone erosion model. Evaluation of the micro-CT of femurs revealed that bone erosion in poncirin-treated mice was markedly attenuated. Results indicate that poncirin exerts anti-osteoclastic effects in vitro and in vivo by suppressing osteoclast differentiation.

In the glucocorticoid-induced osteoporosis mouse study (published in Journal of Bone and Mineral Metabolism, 2012), in vivo and in vitro effects of poncirin in a glucocorticoid-induced osteoporosis (GIO) mouse model were investigated. Seven-month-old male mice were assigned to groups including a GC-treated group receiving 3 mg/kg/day of poncirin. After 8 weeks, bone loss was measured by microcomputed tomography. This represents a rodent in vivo study with a specific dose of 3 mg/kg/day administered over 8 weeks; no human equivalent evidence exists.

5.6 Inflammatory Bowel Disease and Colitis

Poncirin regulates the balance of Th17/Treg cells by inhibiting the differentiation of Th17 cells and promoting the differentiation of Treg cells in an animal model of TNBS-induced colitis. This immunomodulatory mechanism on T-cell subsets is distinct from the direct NF-κB suppression observed in macrophages, and together they suggest multi-target actions in intestinal inflammation, though all evidence remains in animal models.

5.7 Neuroprotection

Poncirin exhibits neuroprotective effects by inhibiting the NOX4/ROS/NLRP3 axis activation in the oxygen-glucose deprivation/reoxygenation (OGD/R) neuronal injury model. This is an in vitro ischemia/reperfusion model. Pharmacological data analysis has also revealed biological applications of poncirin in Alzheimer's disease. These observations are preliminary and derive solely from preclinical models. No clinical neuroprotection trials involving isolated poncirin have been published.

5.8 Analgesic and Antinociceptive Properties

A 2019 murine study tested the anti-allodynic and anti-hyperalgesic potential of poncirin. The analgesic potential of poncirin was evaluated in formalin-, acetic acid-, carrageenan-, and Complete Freund's Adjuvant (CFA)-induced inflammatory pain models in mice. Anti-allodynic and anti-hyperalgesic activities were measured using Von Frey filaments, Randall Selitto, hot plate, and cold acetone tests. The compound poncirin was tested in three different doses (5 mg/kg, 15 mg/kg, or 30 mg/kg, i.p.) in the first two sets of experiments, and 30 mg/kg dose of poncirin produced significant analgesic responses when compared with negative control groups.

Retraction notice: This article was retracted by the editors of BMC Pharmacology and Toxicology in 2023. After publication, concerns were raised regarding high similarity between images in this article and figures in the authors' earlier work. The authors stated that the same control groups were used in both articles; however, the animal descriptions and ethics approval numbers are different in the two publications. The authors provided raw data to address these concerns, but some of the data did not match the published figures. The editor therefore no longer has confidence in the presented data. This retraction materially weakens the evidence base for poncirin's analgesic effects in preclinical pain models, and these findings should be regarded with caution pending independent replication.

5.9 Antidiabetic and Metabolic Effects

Poncirin, described as an orally active flavonoid, has been studied for antidiabetic complications and its ability to improve glucose uptake by activating the PI3K/Akt signaling pathway in insulin-resistant C2C12 cells, with antiglycation capacities. Several in vivo and in vitro pharmacological activity evaluations such as antidiabetic, anti-obesity, anti-inflammatory, antiallergic, antimelanogenic, gastroprotective, anticancer, and neuroprotective effects have been conducted from Ponciri Fructus. These metabolic effects are derived from cell culture and animal studies; no human clinical trials in diabetes or obesity have been reported for poncirin as an isolated compound.

5.10 Anti-Obesity Effects

Ponciri Fructus ameliorated macrophage-mediated inflammation and improved insulin resistance in high-fat-diet-fed mice. The anti-obesity activity of the fruit may be due to its prokinetic effect through the inhibition of nutrient absorption into the bloodstream. These observations concern the whole fruit extract; the contribution of poncirin specifically has not been determined in isolation for these outcomes.

6. Body Systems and Health Areas Associated with Poncirin

• Gastrointestinal system: Gastroprotection, gastric ulcer prevention, prokinetic activity, anti-colitic effects, protection against gastroesophageal reflux disease.
• Immune and inflammatory system: NF-κB inhibition, suppression of COX-2 and iNOS, cytokine modulation (IL-6, TNF-α, IL-1β), Th17/Treg balance regulation.
• Skeletal system: Inhibition of osteoclastogenesis via NFATc1/RANKL pathways, prevention of glucocorticoid-induced bone loss.
• Oncology (preclinical): Apoptosis induction in gastric cancer cells via the extrinsic Fas/FasL pathway; growth inhibition in gastric and other cancer cell lines.
• Nervous system: Neuroprotection via NOX4/ROS/NLRP3 pathway inhibition in ischemia-reperfusion models; preliminary Alzheimer's disease research.
• Metabolic system: Antidiabetic effects via PI3K/Akt pathway in insulin-resistant cells; anti-obesity and anti-hyperglycemic observations in animal studies.
• Antimicrobial (via metabolite): Anti-Helicobacter pylori activity exerted by its gut metabolite ponciretin.

7. Dosage Forms and Reported Dosages

No established human clinical dosage exists for poncirin as an isolated compound. All dosage data in the literature come from preclinical (animal) models or in vitro experiments:

• Gastric protection (rat model): Poncirin (100 mg/kg) significantly inhibited 60.0% of HCl/ethanol-induced gastric lesions and increased mucus content.
• Gastric ulcer lesion index (rat model): Poncirin reduces the gastric ulcer lesion index in a rat model of HCl/ethanol-induced gastritis when administered at doses of 50 and 100 mg/kg.
• Bone protection (mouse model, GIO): In a glucocorticoid-induced osteoporosis mouse model, seven-month-old male mice were treated with 3 mg/kg/day of poncirin for 8 weeks.
• Analgesic (mouse model — retracted study): Poncirin was tested at doses of 5 mg/kg, 15 mg/kg, or 30 mg/kg (i.p.); the 30 mg/kg dose produced significant analgesic responses. Note the retraction of this study as detailed above.
• In vitro anti-cancer (cell culture): Poncirin inhibits the growth of SGC-7901 gastric cancer cells at concentrations ranging from 5 to 25 µg/mL.
• In vitro anti-inflammatory (cell culture): Poncirin (25–100 µM) inhibits LPS-induced NF-κB DNA-binding activity, as well as production of NO and PGE2 in RAW 264.7 cells.
• Ponciri Fructus extract (rat model, BPH): The protective effects of a Ponciri Fructus extract (PFE) on benign prostatic hyperplasia were investigated in male Sprague Dawley rats. PFE was administered daily by oral gavage at a dose level of 200 mg/kg during 4 weeks.

Scientific investigations focusing on bioassay-guided isolation and identification of specific bioactive constituents are limited. An in-depth scientific investigation of Ponciri Fructus focusing on bioassay-guided isolation, mechanism-based pharmacological studies, pharmacokinetic studies, and evaluation of possible toxicities is necessary in the future.

8. Safety Considerations and Notable Interactions

Evidence Gaps in Human Safety Data

There are no published human clinical trials evaluating the safety, tolerability, pharmacokinetics, or drug interactions of poncirin as an isolated supplement. The safety profile presented here is derived entirely from traditional use patterns and preclinical (animal and cell) research.

Traditional Safety Context

Although the ethnomedicinal use of P. trifoliata has a very long history in Korea, Japan, and China, scientific investigations focused on in-depth phytochemistry are limited. Long-term traditional use of Ponciri Fructus preparations in East Asian herbal medicine suggests reasonable tolerability at conventional food or herbal preparation doses, but formal safety evaluations of the isolated compound have not been completed.

Retracted Preclinical Study

The 2019 publication "Anti-hyperalgesic properties of a flavanone derivative Poncirin in acute and chronic inflammatory pain models in mice" was retracted by the editor. This retraction is directly relevant to the safety and pharmacology evidence base for poncirin, as it removes one of the few comprehensive animal dose–response studies from the verifiable literature.

Metabolism and the Ponciretin Metabolite

Poncirin undergoes intestinal bacterial metabolism to yield ponciretin. Ponciretin (5,7-dihydroxy-4′-methoxyflavanone) is the main metabolite and most potently inhibited the growth of H. pylori, with a MIC of 10–20 µg/mL. This metabolic conversion means that the biological activity of orally administered poncirin will depend, in part, on the composition of an individual's gut microbiome. Individuals with altered gut flora (e.g., from antibiotic use or gastrointestinal disease) may metabolize poncirin to ponciretin at different rates, potentially affecting biological outcomes.

Bitter Taste and Gastrointestinal Tolerability

Poncirin is a flavanone glycoside with a bitter taste. Like other bitter flavanone glycosides (notably naringin), high oral doses of poncirin-rich preparations may cause gastrointestinal discomfort due to the inherent bitterness and the direct irritant potential of concentrated polyphenols on the gastric mucosa, though direct evidence for this with poncirin specifically has not been formally characterized.

Absence of Clinical Interaction Data

No published studies have examined drug–drug or drug–food interactions for isolated poncirin in humans or in robust pharmacokinetic models. Given that poncirin belongs to the flavanone class of citrus polyphenols, and given what is known about the related compounds hesperidin and naringenin, potential interactions with cytochrome P450 enzyme systems are plausible but have not been characterized for poncirin specifically. An in-depth scientific investigation of Ponciri Fructus focusing on pharmacokinetic studies and evaluation of possible toxicities is necessary in the future.

Overall Evidence Strength Assessment

The totality of scientific evidence for poncirin's biological activities is preliminary and preclinical. Several in vivo and in vitro pharmacological activity evaluations such as antidiabetic, anti-obesity, anti-inflammatory, antiallergic, antimelanogenic, gastroprotective, anticancer, and neuroprotective effects have been conducted from Ponciri Fructus. The mechanistic in vitro evidence is informative for understanding pharmacological pathways. Multiple rodent in vivo models provide proof-of-concept data for anti-inflammatory, gastroprotective, and bone-protective effects. However, the absence of human pharmacokinetic data, dose-finding studies, and randomized controlled trials means that none of these effects can be claimed to be established in humans. The retraction of one key analgesic study further narrows the reliable preclinical evidence base.

References

• PubChem — Poncirin (CID 442456), National Institutes of Health
• Zhu X et al. "Characterization, Purification of Poncirin from Edible Citrus Ougan and Its Growth Inhibitory Effect on Human Gastric Cancer Cells SGC-7901." PMC, 2013.
• Saralamma VVG et al. "Poncirin Induces Apoptosis in AGS Human Gastric Cancer Cells through Extrinsic Apoptotic Pathway by up-Regulation of Fas Ligand." International Journal of Molecular Sciences, 2015. PMC4613330.
• Bioactive Chemical Constituents and Pharmacological Activities of Ponciri Fructus. Molecules, 2023. PMC9821892.
• Bioactive Chemical Constituents and Pharmacological Activities of Ponciri Fructus. MDPI Molecules, 2023.
• Poncirus trifoliata (L.) Raf.: Chemical composition, antioxidant properties and hypoglycaemic activity via the inhibition of α-amylase and α-glucosidase enzymes. ScienceDirect, 2016.
• Phytotherapeutic effects of the fruits of Poncirus trifoliata (L.) Raf. on cancer, inflammation, and digestive dysfunction. Phytotherapy Research, 2018.
• Chun KH et al. "Poncirin Inhibits Osteoclast Differentiation and Bone Loss through Down-Regulation of NFATc1 In Vitro and In Vivo." Biomolecules and Therapeutics, 2020. PMC7327144.
• Yoon HY, Won YY, Chung YS. "Poncirin prevents bone loss in glucocorticoid-induced osteoporosis in vivo and in vitro." Journal of Bone and Mineral Metabolism, 2012. PMID 22407507.
• Lee JH et al. "Protective effects of neohesperidin and poncirin isolated from the fruits of Poncirus trifoliata on potential gastric disease." Phytotherapy Research, 2009. PMID 19367677.
• Kim DH et al. "Anti-Helicobacter pylori activity of the metabolites of poncirin from Poncirus trifoliata by human intestinal bacteria." Biological and Pharmaceutical Bulletin, 1999. PMID 10328566.
• Inhibitory effects of Ponciri Fructus on testosterone-induced benign prostatic hyperplasia in rats. PMC5543435.
• Afridi R et al. "Retraction Note: Anti-hyperalgesic properties of a flavanone derivative Poncirin in acute and chronic inflammatory pain models in mice." BMC Pharmacology and Toxicology, 2023.
• Therapeutic effects of Poncirus fructus on colonic dysfunction and visceral pain in a zymosan-induced irritable bowel syndrome mouse model. Frontiers in Pharmacology, 2025.
• Han HY et al. "Autophagic Cell Death by Poncirus trifoliata Rafin., a Traditional Oriental Medicine, in Human Oral Cancer HSC-4 Cells." Evidence-Based Complementary and Alternative Medicine, 2015.
• Therapeutic Potential of Poncirin Against Numerous Human Health Complications. Endocrine, Metabolic & Immune Disorders — Drug Targets, 2021.
• Trifoliate orange — Wikipedia
• Han AR et al. "A New Flavanone Glycoside from the Dried Immature Fruits of Poncirus trifoliata." Chemical and Pharmaceutical Bulletin, 2007.
• Anti-inflammatory effects of naringinase treated ethanol extracts of Poncirus trifoliata fruit. Food Science and Biotechnology, 2025.
• Kang GD, Kim DH. "Poncirin and its metabolite ponciretin attenuate colitis in mice by inhibiting LPS binding on TLR4 of macrophages and correcting Th17/Treg imbalance." Journal of Ethnopharmacology, 2016.